Its capability to counteract the Ang II-evoked vascular dysfunction and high blood pressure inhibiting overexpression and activation of AT1R/p-ERK1/2/Rac1-GTP signalling, strongly candidate PG1, as a novel potential peptide to be used as a preventive strategy aimed at preventing the incidence of overt hypertension and its related vascular complications. This evidence concerns the gene MAPK3 and blood pressure trait.